• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Buyouts

Cinven invests in Barentz

  • Alessia Argentieri
  • Alessia Argentieri
  • 26 November 2019
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Cinven has acquired a majority stake in Barentz, a Dutch company specialising in the production of ingredients for the pharmaceutical, cosmetics and food industries.

Unquote understands that this is the last investment made by Cinven via its sixth fund, which closed on €7bn in June 2016 and is now fully deployed. In addition to the equity from the fund, a debt package composed of a term loan B and a revolving credit facility was provided to support the acquisition of Barentz.

Cinven launched a new buyout vehicle in 2018, Seventh Cinven Fund, which held a final close on €10bn in May 2019, exceeding its €8bn target. The fund focuses on European buyouts and selective North American investments, and targets six main sectors: business services, consumer, financial services, healthcare, industrials, telecommunications, media and technology. It plans to make 10-12 deals and deploy equity tickets from €200m.

Barentz

  • DEAL:

    Buyout

  • LOCATION:

    Hoofddorp

  • SECTOR:

    Food products

  • FOUNDED:

    1953

  • TURNOVER:

    €1bn (2018)

  • STAFF:

    1,100

The fund has already inked its first investment in life sciences supplies provider LGC, which was acquired by a consortium of Cinven, Astorg and the Abu Dhabi Investment Authority for £3bn earlier this month.

Cinven intends to boost Barentz's growth, both organically and through integrating acquisitions, as well as expand its operations into new geographies, and invest in its infrastructure and R&D capabilities.

Company
Established in 1953 and headquartered in Hoofddorp, Barentz is a speciality ingredients producer and distributor for the food, pharmaceutical, personal care and animal nutrition markets.

The company sources branded speciality ingredients from manufacturers worldwide and provides pre-mixing, blending, ingredient formulation and ingredient testing in its state-of-the-art production facilities based in Europe, North America and Asia.

Barentz has operations in more than 60 countries with a strong presence in Europe and Asia, and a growing presence in North America and Latin America. It employs 1,100 staff, sources ingredients from 1,000 suppliers and serves 15,000 customers. Unquote understands that the company generates revenues of around €1bn. 

People
Cinven
– Ben Osnabrug (partner).
Barentz – Hidde van der Wal (CEO).

Advisers
Equity
– 1602 Capital Partners (corporate finance).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Buyouts
  • Benelux
  • Consumer
  • Cinven
  • Netherlands

More on Buyouts

Clinical trials and biotechnology
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • Buyouts
  • 04 September 2023
EMEA Public to Private M&A
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • Investments
  • 04 September 2023
HR software solutions providers
Main Capital’s Assessio to be sold to Pollen Street

Recruitment software company tripled in revenue under Main Capital’s ownership

  • Buyouts
  • 25 August 2023
Ice cream
Exponent divests ‘significant' stake in Meadow to Canadian investor

Since 2018, GP has diversified food ingredients company's focus beyond commodity dairy

  • Exits
  • 22 August 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013